All patients
Age < 65y (younger) Age > 65y Age > 75y (older) cancer type (metastatic) cancer type (recurrent) ECOG 0 ECOG 1 Gender, female Gender, male P16 negative (HPV) P16 positive (HPV) PDL1 (CPS < 1) PDL1 (CPS >1) PDL1 (TPS <50%) PDL1 (TPS >50%) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
head and neck cancer squamous cell cancer (HNSCC), pembrolizumab alone vs. cetuximab based chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.83 [0.70; 0.99]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.78 [0.64; 0.96]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.61 [0.45; 0.83]
0.76 [0.66 ; 0.89 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019 3 32% 1,368 moderate not evaluable deaths (OS) (extension)detailed results KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.74 [0.61; 0.90]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.58 [0.44; 0.77]
0.67 [0.53 ; 0.85 ] KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019 2 47% 767 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.34 [1.13; 1.59]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 1.16 [0.96; 1.40]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.99 [0.75; 1.30]
1.18 [1.01 ; 1.39 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019 3 45% 1,368 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.25; 0.53]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.44 [0.29; 0.66]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.11 [0.06; 0.20]
0.27 [0.13 ; 0.55 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019 3 87% 1,368 moderate not evaluable AE (any grade)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.22; 0.44]
0.31 [0.22 ; 0.44 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.84 [0.48; 1.48]
0.84 [0.48 ; 1.48 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.23; 0.55]
0.36 [0.23 ; 0.55 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable TRAE (any grade)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.02; 0.09]
0.05 [0.02 ; 0.09 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.06; 0.13]
0.09 [0.06 ; 0.13 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.35 [0.09; 1.34]
0.35 [0.09 ; 1.34 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
1.92 [0.06 ; 57.35 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.01; 0.16]
0.04 [0.01 ; 0.16 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.16 [0.02; 1.31]
0.16 [0.02 ; 1.31 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.02 [0.01; 0.07]
0.02 [0.01 ; 0.07 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
0.96 [0.02 ; 48.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.13; 6.84]
0.96 [0.13 ; 6.84 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
0.96 [0.02 ; 48.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94]
0.12 [0.01 ; 0.94 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62]
0.19 [0.02 ; 1.62 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (P vs C ; all population), 2019 5.79 [0.29; 116.06]
5.79 [0.29 ; 116.06 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.07; 0.92]
0.25 [0.07 ; 0.92 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.07 [0.02; 0.23]
0.07 [0.02 ; 0.23 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.08; 0.46]
0.19 [0.08 ; 0.46 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65]
3.85 [0.17 ; 85.65 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
1.92 [0.06 ; 57.35 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
1.92 [0.06 ; 57.35 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.06; 1.57]
0.31 [0.06 ; 1.57 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
0.03 [0.00 ; 0.47 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.26 [0.14; 0.49]
0.26 [0.14 ; 0.49 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.13 [0.03; 0.58]
0.13 [0.03 ; 0.58 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
0.96 [0.02 ; 48.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.48 [0.02; 14.29]
0.48 [0.02 ; 14.29 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
0.03 [0.00 ; 0.47 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65]
3.85 [0.17 ; 85.65 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results Out of scale KEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.11]
0.01 [0.00 ; 0.11 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
0.96 [0.02 ; 48.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.42 [0.46; 12.55]
2.42 [0.46 ; 12.55 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47]
0.11 [0.02 ; 0.47 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.29 [0.11; 0.73]
0.29 [0.11 ; 0.73 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80]
0.05 [0.00 ; 0.80 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.00; 0.27]
0.04 [0.00 ; 0.27 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
0.96 [0.02 ; 48.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
0.96 [0.02 ; 48.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.01; 1.73]
0.09 [0.01 ; 1.73 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.06; 15.37]
0.96 [0.06 ; 15.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62]
0.19 [0.02 ; 1.62 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.93 [0.35; 10.60]
1.93 [0.35 ; 10.60 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.24 [0.13; 0.44]
0.24 [0.13 ; 0.44 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.08; 1.16]
0.31 [0.08 ; 1.16 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.10 [0.06; 0.18]
0.10 [0.06 ; 0.18 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.28 [0.08; 1.03]
0.28 [0.08 ; 1.03 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.23 [0.05; 1.11]
0.23 [0.05 ; 1.11 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83]
2.26 [0.58 ; 8.83 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.60 [0.26; 1.42]
0.60 [0.26 ; 1.42 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
0.03 [0.00 ; 0.47 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Gastrointestinal disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.33 [0.20; 0.56]
0.33 [0.20 ; 0.56 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable General disorders and administration site conditions AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.42 [0.23; 0.75]
0.42 [0.23 ; 0.75 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Hypertension AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 7.74 [0.41; 147.13]
7.74 [0.41 ; 147.13 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
0.96 [0.02 ; 48.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.38 [0.07; 1.97]
0.38 [0.07 ; 1.97 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Leucopenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
0.03 [0.00 ; 0.47 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.51 [0.33; 0.77]
0.51 [0.33 ; 0.77 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.08; 0.75]
0.25 [0.08 ; 0.75 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.44]
0.03 [0.00 ; 0.44 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Nervous system disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.40 [0.18; 0.85]
0.40 [0.18 ; 0.85 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.09]
0.01 [0.00 ; 0.09 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Pneumonitis AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.80 [0.41; 1.56]
0.80 [0.41 ; 1.56 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47]
0.11 [0.02 ; 0.47 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Renal and urinary disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.15 [0.35; 3.81]
1.15 [0.35 ; 3.81 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Respiratory, thoracic and mediastinal disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.17 [1.12; 4.18]
2.17 [1.12 ; 4.18 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Sepsis AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.91 [0.58; 14.53]
2.91 [0.58 ; 14.53 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.61 [0.58; 4.50]
1.61 [0.58 ; 4.50 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80]
0.05 [0.00 ; 0.80 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.25]
0.03 [0.00 ; 0.25 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Vascular disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.76 [0.35; 1.64]
0.76 [0.35 ; 1.64 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94]
0.12 [0.01 ; 0.94 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Weight decreased AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83]
2.26 [0.58 ; 8.83 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-03 14:18 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 6,275,106,104,105,276,103,277,102,109,278,101,192,114
- treatments: 359,575,577,576,869